High-throughput microfluidic technology for developing small 3D tissues**

传统的基于细胞的测定提供了在二维（2D）培养系统中研究细胞-细胞、细胞-组织和细胞-药物相互作用的机会。这些测定广泛用于筛选在组织中的广泛生物事件中调节特定靶标的分子库。然而，使用传统的2D模型进行基于表型细胞的筛选的成本对于许多公司进行大规模分子筛选是令人望而却步的。此外，现有的3D组织模型仍然不能概括真实的3D组织的基本要求，例如在受控灌注系统下细胞与3D基质的相互作用。在这个项目中，我们将开发一种新技术，用于生成具有更小尺寸的逼真3D组织，用于制造用于细胞工程或组织治疗的有效生物分子。这种技术使得能够制造具有模拟细胞-细胞、细胞-组织和细胞-生物分子相互作用的更逼真的组织，并且有助于在高通量系统中制造与非常小体积的生物分子相互作用的小组织。这种3D组织模型将大大降低测试生物分子性能的成本，使靶分子的大规模筛选变得负担得起。这项工作还将消除小组织之间交叉污染的挑战，这是所有现有3D组织分析的关键挑战。这些3D组织模型将有利于SV ChemBiotech开发具有成本效益的组织模型，并大幅降低测试生物分子性能的成本，通过使靶分子的大规模筛选变得负担得起，为公司提供进入新市场的机会。

Conventional cell-based assays offer the opportunity to investigate cell-cell, cell-tissue, and cell-drug interactions in two-dimensional (2D) culture systems. These assays are used extensively to perform screening a library of molecules that modulate a certain target among a broad range of biological events in tissues. However, the cost of phenotypic cell-based screening using conventional 2D models is prohibitive for many companies for large-scale screening of molecules. Also, the existing 3D tissue models do not still recapitulate basic requirements of a real 3D tissue such as the interaction of cells with the 3D matrix under controlled perfusion system. In this project, we will develop a new technology for generating realistic 3D tissues with much smaller size, useful to make effective biomolecules for engineering of cells or treatment of tissues. Such technology enables making more realistic tissues with mimetic cell-cell, cell-tissue, and cell-biomolecules interactions, and helps to make small tissues interacting with a very small volume of biomolecules in a high-throughput system. This 3D tissue model will drastically reduce the cost of testing biomolecules performance, making the large-scale screening of target molecules affordable. This work will also eliminate the challenge of cross-contamination among small tissues, something that is a critical challenge in all existing 3D tissue assays. These 3D tissue models will benefit SV ChemBiotech in developing cost-effective tissue models and drastically reducing the cost of testing biomolecules performance, providing the access to a new market for the company via making the large-scale screening of target molecules affordable.****